News Channels

04 Dec 2019 Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
04 Dec 2019 Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
04 Dec 2019 Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
04 Dec 2019 QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer
04 Dec 2019 Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
04 Dec 2019 Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
04 Dec 2019 Censa Pharmaceuticals Announces CNSA-001 Met Primary and Secondary Endpoints in Phase 2 Trial in Patients with PKU
04 Dec 2019 CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications
04 Dec 2019 Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe
04 Dec 2019 Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
04 Dec 2019 Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
04 Dec 2019 FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
03 Dec 2019 Announcement of Joint Development Agreement of Aflibercept Biosimilars with Kishi Kasei Co., Ltd.
03 Dec 2019 IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets
03 Dec 2019 INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
03 Dec 2019 OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
03 Dec 2019 Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone
03 Dec 2019 NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
03 Dec 2019 1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
03 Dec 2019 Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up